ELEV

Elevation Oncology

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About ELEV

Elevation Oncology, Inc.

A clinical stage biopharmaceutical company that developing precision medicines for genomically defined cancers

Industry

Biological Technology

Established Date

04/29/2019

Listing Date

06/25/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.elevationoncology.com

Security Type

Common stock

Office address

101 Federal Street, Suite 1900, Boston, Massachusetts 02110

Business

Introduction

Elevation Oncology, Inc., was incorporated under the laws of the State of Delaware on April 29, 2019. The Company is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients with a range of solid tumors with unmet medical needs. The company is rethinking drug development, seeking innovative, selective cancer therapies that can match patients' unique tumor characteristics. The company's lead product candidate, EO-3021 (also known as SYSA 1801 or CPO 102), is an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target that selectively delivers cytotoxic payloads directly to cancer cells expressing Claudin 18.2.

Company Financials

EPS

ELEV has released its 2024 Q4 earnings. EPS was reported at -0.18, versus the expected -0.22, beating expectations. The chart below visualizes how ELEV has performed over recent quarters, highlighting trends in earnings surprises.